This website uses cookies so that we can provide you with the best user experience possible. Our Cookie Notice is part of our Privacy Policy and explains in detail how and why we use cookies. To take full advantage of our website, we recommend that you click on “Accept All”. You can change these settings at any time via the button "Update Cookie Preferences" in our Cookie Notice.
Technical cookies are required for the site to function properly, to be legally compliant and secure. Session cookies only last for the duration of your visit and are deleted from your device when you close your internet browser. Persistent cookies, however, remain and continue functioning on repeat visits.
CMS does not use any cookie based Analytics or tracking on our websites; see details here.
Personalisation cookies collect information about your website browsing habits and offer you a personalised user experience based on past visits, your location or browser settings. They also allow you to log in to personalised areas and to access third party tools that may be embedded in our website. Some functionality will not work if you don’t accept these cookies.
25/11/2014
Munich - Curetis, a molecular diagnostics company based in Holzgerlingen near Stuttgart, has extended its Series B financing round by EUR 14.5 million.
The Series B round was originally completed in April 2013. Its lead investor, HBM Partners, one of the world's leading investors in the healthcare/medical sector, has also joined in the extension funding on a pro rata basis, together with the other existing investors aeris Capital, BioMed Invest, CD Venture, Forbion Capital, LSP Life Sciences Partners, Roche Venture Fund, the management of Curetis and private angel investors, generating a total of EUR 7.5 million. Biotechnology company QIAGEN and the LSP Health Economics Fund are additionally providing a total of EUR 7 million as new investors. This round of financing increases the equity capital raised by Curetis AG to more than EUR 63.5 million. The funding is earmarked for further growth and to help prepare the company for future exit options such as strategic partnerships, M&A or an initial public offering (IPO).
A team from CMS Hasche Sigle led by lead partner Stefan-Ulrich Müller advised Curetis on all legal aspects of the extension. The firm also provided legal advice on the original Series B round of financing. It also advised LSP Life Sciences Partners during the Series A financing round for Curetis in 2009, as well as Curetis and the original investors on the extension of Series A in 2011.
Established in 2007, Curetis AG focuses on the development and commercialisation of products for the diagnosis of serious infectious diseases. QIAGEN N.V. is listed on the TecDAX in Germany. It generated sales of more than USD 1.3 billion in 2013. LSP Life Sciences Partners is a leading investment firm in the European healthcare sector with offices in Amsterdam, Munich and Boston. HBM Partners manages healthcare investments amounting to around USD 1 billion worldwide.
Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert
Katrin Bauer, all Venture Capital
Stefan Lehr, Competition
Michaela Ott, Tax
Press Contact
[email protected]
Social Media cookies collect information about you sharing information from our website via social media tools, or analytics to understand your browsing between social media tools or our Social Media campaigns and our own websites. We do this to optimise the mix of channels to provide you with our content. Details concerning the tools in use are in our privacy policy.